Wanhuida Intellectual Property

Wanhuida Intellectual Property is a leading IP service provider in China. It has two main legal entities, Wanhuida IP Agency and Wanhuida Law Firm, with offices covering all major IP hubs in China. Wanhuida supplies a full range of IP services, from procurement of all forms of IP rights to dispute resolution involving patents, trademarks, unfair competition and other IP-related rights, protecting and defending its client’s interests and help advancing China’s legal fronts.

• Competition/antitrust
• Dispute resolution
• Regulatory
• Intellectual property

Trademark
Ren Haiyan (Ms)
renhaiyan@wanhuida.com

Recent case highlights:

• Advising MICHELIN in a trademark infringement suit against a Chinese infringer, which exhibited and promoted toys using the "Tire man device", obtained favourable retrial decision, cessation and damages of RMB 100,000. The retrial court ascertains that using a figurative trademark as a three-dimensional object constitutes trademark infringement. The case is selected as one of the SPC’s 50 exemplary IPR cases of 2020.
• Advising ABB in bringing a private criminal prosecution against a counterfeit seller before a local Court in Wuhu, which found exporter Teaton and its owner Zhang guilty of selling counterfeit goods, sentencing Zhang to 3.5-year imprisonment and imposing RMB 800,000 fines to Zhang and RMB 850,000 fines to Teaton. The decision was upheld by the court of appeal. The case is selected as one of the SPC’s 50 exemplary IPR cases of 2020.
• Representing Wyeth in securing a favorable decision in a civil appeal proceeding against a long-term infringer Guangzhou Wyeth Baby Products Ltd. et al. The Zhejiang High Court upheld the decision rendered by the Hangzhou Intermediate Court, which found trademark infringement and unfair competition, ordered cessation and granted punitive damages of RMB 30 million and reasonable legal expenditure of RMB 550,000.

Patent
Dr. S. Sam Li
samli@wanhuida.com

Recent case highlights:

• Helping Bayer fend off the invalidity challenges launched by rivals against its compound patent of blockbuster anticoagulant drug rivaroxaban, a case selected as one of the CNIPA’s Top Ten Patent Reexamination and Invalidation Cases in 2020.
• Advising P&G in fending off an unreasonable patent infringement suit initiated by a Chinese patentee claiming whopping damages as high as RMB 100 million before the Shanghai IP Court by having the patentee’s invention invalidated.
• Representing Bayer in enforcing its pharmaceutical patent over the anti-tumor compound sorafenib by initiating an administrative action against a local infringer offering to sell the patented products. The Shanghai IPO granted Bayer's petition and ordered cessation of the infringement. The case is selected as one of the CNIPA’s Ten Exemplary Patent Administrative Enforcement Cases of 2019.

• Consumer goods and services
• Industrials and manufacturing
• Media and entertainment
• Technology and telecommunications

Shanghai · Guangzhou · Shenzhen · Chongqing · Tianjin · Hangzhou · Suzhou · Ningbo · Hong Kong